Breakthrough Device Designation from the FDA

Breakthrough Device Designation from the FDA

  We are thrilled to announce that we just received a Breakthrough Device Designation from the United States Food and Drug Administration (FDA) for our novel hip cartilage repair technology. The intent of the Breakthrough Devices Program1 is to help patients have...
October Newsletter

October Newsletter

The October issue of the CytexOrtho newsletter covers our progression toward clinical trials, discussions with the FDA, and our new CRP award from NIH! If you would like to receive a copy of our future newsletters, be sure to sign up for our mailing lists via the...
In WRAL Techwire

In WRAL Techwire

CytexOrtho is in the news! WRAL Techwire featured a Startup Spotlight article about CytexOrtho on Monday, August 8th, 2022.  According to WRAL: “Startup Spotlight is a regular feature in WRAL Techwire, bringing attention to promising emerging companies across the...
New Publication

New Publication

We are pleased to announce that our research is featured on the cover of the August 2022 issue of the Journal of Orthopaedic Research!   This review provides a summary of the research and development behind our osteochondral repair implant. The summary was the basis...